Myung Soo Park
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Myung Soo Park has a total of 69 co-authors. Here are the top co-authors by number of shared publications:
- Eung Ju Kim
Division of Cardiology, Department of Internal Medicine, Korea University Guro Hospital , Seoul
5 shared publications - Dae Young Cheon
Division of Cardiology, Department of Internal Medicine, Hallym University Dongtan Sacred Heart Hospital, Hwaseong, Korea
4 shared publications - Jeen Hwa Lee
Division of Cardiology, Department of Internal Medicine, Hallym University Dongtan Sacred Heart Hospital, Hwaseong, Korea
4 shared publications Seongwoo Han
Department of Cardiology, Hallym University Dongtan Sacred Heart Hospital , Hwaseong
3 shared publications- Seongwoo Han
Division of Cardiology, Department of Internal Medicine, Hallym University Dongtan Sacred Heart Hospital, Hwaseong, Korea
3 shared publications - Sunki Lee
Cardiovascular center, Korea University Guro Hospital, 148 Gurodong-ro, Guro-gu, Seoul, 08308, Republic of Korea, 82 02-2626-3022, 82 02-2626-2024
3 shared publications
Latest Publications
- Open Access
- 19 October 2026
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 15, e104230
Clinical Effectiveness of AI-Based Cardiac Arrest Prediction System for General Ward Patients (VITAL-MD): Protocol for a Multicenter Pragmatic Stepped Wedge Cluster Randomized Controlled Trial
Background: In-hospital cardiac arrest (IHCA) remains a frequent and devastating event, and conventional early warning scores (EWSs) coupled with rapid response systems (RRSs) have shown inconsistent effects on patient-centered outcomes, largely owing to limited predictive accuracy and high false-alarm burden. AI-based EWSs (AI-EWSs) have demonstrated superior discrimination retrospectively, but high-quality prospective evidence in true external validation environments remains scarce. Existing AI-EWS trials have either been confined to internal-development settings or bundled the algorithm with specific implementation infrastructure, leaving the stand-alone effect of AI-based software as a medical device (AI-SaMD) on patient outcomes uncharacterized. Objective: This trial will evaluate whether implementation of AI-SaMD (VUNO Med -DeepCARS ) as a stand-alone clinical decision-support tool in routine general-ward care reduces IHCA compared with usual care based on conventional EWSs. Methods: The VITAL-MD trial (validation of an AI-based clinical deterioration prediction model on patient outcomes through a stepped-wedge cluster randomized trial [SW-CRT] multicenter evaluation of DeepCARS) is a pragmatic, multicenter, SW-CRT conducted at 4 tertiary academic hospitals in the Republic of Korea. Six tertiary academic hospitals were assessed for eligibility based on inpatient capacity, RRS operating hours aligned with the national RRS pilot program, and no prior AI-SaMD use. All adult patients aged 19 years or older admitted to general wards during the 12-month trial period are included; patients younger than 19 years, or with no documented vital signs throughout hospitalization, are excluded. The 4 sites are randomized to sequentially transition from preimplementation (usual care) to postimplementation (AI-SaMD–guided care) in 4 steps separated by 7-day washout periods. DeepCARS generates real-time risk scores from 4 vital signs and integrates into the existing electronic medical record interface without altering RRS workflows. The primary outcome is the incidence of general-ward IHCA, defined per the Utstein guidelines, among the target cohort (defined as patients exceeding the alert threshold at least once). Assuming a baseline IHCA incidence of 6.70%, a 40% relative risk reduction, an intracluster correlation coefficient of 0.01, and 350 patients per cluster-period, 7002 target-cohort patients (total enrollment approximately 72,695) provide 80% power. Analyses follow the intention-to-treat principle using generalized linear mixed models adjusting for prespecified covariates, with prespecified sensitivity, subgroup, and compliance analyses. Results: The trial was registered with the Clinical Research Information Service (KCT0010243) on February 28, 2025. Recruitment was conducted from April 1, 2025, to March 31, 2026. All 4 sites completed transition to the postimplementation period, and data cleaning is currently underway before the final database lock, with primary results expected in 2027. Conclusions: VITAL-MD will provide the first large-scale, multicenter randomized evidence evaluating whether an AI-EWS, deployed as a stand-alone device in external validation environments and benchmarked against real-world standard-of-care practice, improves patient-centered outcomes for general-ward patients, advancing the evaluation of AI-SaMD from retrospective diagnostic accuracy toward prospective, action-anchored clinical utility.
- 19 October 2026
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 15, e104230
Open AccessClinical Effectiveness of AI-Based Cardiac Arrest Prediction System for General Ward Patients (VITAL-MD): Protocol for a Multicenter Pragmatic Stepped Wedge Cluster Randomized Controlled Trial
Background: In-hospital cardiac arrest (IHCA) remains a frequent and devastating event, and conventional early warning scores (EWSs) coupled with rapid response systems (RRSs) have shown inconsistent effects on patient-centered outcomes, largely owing to limited predictive accuracy and high false-alarm burden. AI-based EWSs (AI-EWSs) have demonstrated superior discrimination retrospectively, but high-quality prospective evidence in true external validation environments remains scarce. Existing AI-EWS trials have either been confined to internal-development settings or bundled the algorithm with specific implementation infrastructure, leaving the stand-alone effect of AI-based software as a medical device (AI-SaMD) on patient outcomes uncharacterized. Objective: This trial will evaluate whether implementation of AI-SaMD (VUNO Med -DeepCARS ) as a stand-alone clinical decision-support tool in routine general-ward care reduces IHCA compared with usual care based on conventional EWSs. Methods: The VITAL-MD trial (validation of an AI-based clinical deterioration prediction model on patient outcomes through a stepped-wedge cluster randomized trial [SW-CRT] multicenter evaluation of DeepCARS) is a pragmatic, multicenter, SW-CRT conducted at 4 tertiary academic hospitals in the Republic of Korea. Six tertiary academic hospitals were assessed for eligibility based on inpatient capacity, RRS operating hours aligned with the national RRS pilot program, and no prior AI-SaMD use. All adult patients aged 19 years or older admitted to general wards during the 12-month trial period are included; patients younger than 19 years, or with no documented vital signs throughout hospitalization, are excluded. The 4 sites are randomized to sequentially transition from preimplementation (usual care) to postimplementation (AI-SaMD–guided care) in 4 steps separated by 7-day washout periods. DeepCARS generates real-time risk scores from 4 vital signs and integrates into the existing electronic medical record interface without altering RRS workflows. The primary outcome is the incidence of general-ward IHCA, defined per the Utstein guidelines, among the target cohort (defined as patients exceeding the alert threshold at least once). Assuming a baseline IHCA incidence of 6.70%, a 40% relative risk reduction, an intracluster correlation coefficient of 0.01, and 350 patients per cluster-period, 7002 target-cohort patients (total enrollment approximately 72,695) provide 80% power. Analyses follow the intention-to-treat principle using generalized linear mixed models adjusting for prespecified covariates, with prespecified sensitivity, subgroup, and compliance analyses. Results: The trial was registered with the Clinical Research Information Service (KCT0010243) on February 28, 2025. Recruitment was conducted from April 1, 2025, to March 31, 2026. All 4 sites completed transition to the postimplementation period, and data cleaning is currently underway before the final database lock, with primary results expected in 2027. Conclusions: VITAL-MD will provide the first large-scale, multicenter randomized evidence evaluating whether an AI-EWS, deployed as a stand-alone device in external validation environments and benchmarked against real-world standard-of-care practice, improves patient-centered outcomes for general-ward patients, advancing the evaluation of AI-SaMD from retrospective diagnostic accuracy toward prospective, action-anchored clinical utility.
- Open Access
- 20 August 2026
- Published by JMIR Publications Inc. in JMIR Medical Informatics
- Vol. 14, e87142
Prediction of Atrial Fibrillation Occurrence With Handheld Mobile Electrocardiogram: Deep Learning Model Development Using Real-World Data
Background: Atrial fibrillation (AF) is a common arrhythmia associated with an increased risk of stroke and heart failure. To improve prevention, recent studies have used deep learning models to identify at-risk individuals early from normal sinus rhythm (NSR). However, studies using mobile electrocardiogram (mECG) in outpatient, real-world settings remain underexplored. Objective: The study aimed to develop and evaluate deep learning models using a real-world limb-lead mECG database to predict the short-term occurrence of AF from NSR recordings. Methods: mECG data were collected from real-world users of commercially available handheld mECG devices capable of capturing 6 limb leads. AF occurrence was defined as an AF event within a predefined time window (7, 14, or 31 d) from the date of the NSR recording. Transformer-based prediction models were developed for limb-lead and lead I input configurations using a multistage training approach with self-supervised pretraining and domain adaptation, drawing on both open, large-scale clinical 12-lead ECG and proprietary real-world mECG databases. The models were evaluated in an internal real-world cohort and explored in an external cohort as a proof of concept via time-to-event analysis. Results: Between March 2023 and November 2024, 386,519 mECGs were acquired from 8206 users. There were 18,949, 25,206, and 33,524 AF incidences within the 7-, 14-, and 31-day time windows. The models were pretrained with 787,257 12-lead ECGs and 202,689 mECGs, then fine-tuned to predict AF occurrence using 97,447 labeled mECGs. The limb-lead models achieved areas under the receiver operating characteristic curves (AUROCs) of 0.793, 0.785, and 0.787 for 7-, 14-, and 31-day predictions on the internal cohort, respectively, with a user-level AUROC of 0.702 for the 31-day prediction. These models significantly outperformed the lead I models ( P <.001), supporting the value of multilead configurations. The multistage pretraining was essential, as single-source pretraining yielded lower AUROCs of 0.555 with mECGs only and 0.761 with 12-lead ECGs only for the 31-day prediction. In the subgroup analysis, AUROC values were consistent across age, PR interval, and corrected QT interval, but showed disparities ( P <.001) by sex (0.713 in females vs 0.794 in males) and by QRS duration (0.583 in ≥120 ms vs 0.796 in P =.03); Cox proportional hazards regression yielded a hazard ratio of 1.49 (95% CI 1.06‐2.09) per 0.1 increase in model output. Conclusions: Our findings elucidate the feasibility of deep learning–based AF risk prediction using single-NSR recordings from mobile devices, highlighting the potential for remote AF management in real-world populations. The model output may serve as a risk indicator to support opportunistic AF screening, prompting further clinical evaluation and informing decisions about more intensive monitoring.
- 20 August 2026
- Published by JMIR Publications Inc. in JMIR Medical Informatics
- Vol. 14, e87142
Open AccessPrediction of Atrial Fibrillation Occurrence With Handheld Mobile Electrocardiogram: Deep Learning Model Development Using Real-World Data
Background: Atrial fibrillation (AF) is a common arrhythmia associated with an increased risk of stroke and heart failure. To improve prevention, recent studies have used deep learning models to identify at-risk individuals early from normal sinus rhythm (NSR). However, studies using mobile electrocardiogram (mECG) in outpatient, real-world settings remain underexplored. Objective: The study aimed to develop and evaluate deep learning models using a real-world limb-lead mECG database to predict the short-term occurrence of AF from NSR recordings. Methods: mECG data were collected from real-world users of commercially available handheld mECG devices capable of capturing 6 limb leads. AF occurrence was defined as an AF event within a predefined time window (7, 14, or 31 d) from the date of the NSR recording. Transformer-based prediction models were developed for limb-lead and lead I input configurations using a multistage training approach with self-supervised pretraining and domain adaptation, drawing on both open, large-scale clinical 12-lead ECG and proprietary real-world mECG databases. The models were evaluated in an internal real-world cohort and explored in an external cohort as a proof of concept via time-to-event analysis. Results: Between March 2023 and November 2024, 386,519 mECGs were acquired from 8206 users. There were 18,949, 25,206, and 33,524 AF incidences within the 7-, 14-, and 31-day time windows. The models were pretrained with 787,257 12-lead ECGs and 202,689 mECGs, then fine-tuned to predict AF occurrence using 97,447 labeled mECGs. The limb-lead models achieved areas under the receiver operating characteristic curves (AUROCs) of 0.793, 0.785, and 0.787 for 7-, 14-, and 31-day predictions on the internal cohort, respectively, with a user-level AUROC of 0.702 for the 31-day prediction. These models significantly outperformed the lead I models ( P <.001), supporting the value of multilead configurations. The multistage pretraining was essential, as single-source pretraining yielded lower AUROCs of 0.555 with mECGs only and 0.761 with 12-lead ECGs only for the 31-day prediction. In the subgroup analysis, AUROC values were consistent across age, PR interval, and corrected QT interval, but showed disparities ( P <.001) by sex (0.713 in females vs 0.794 in males) and by QRS duration (0.583 in ≥120 ms vs 0.796 in P =.03); Cox proportional hazards regression yielded a hazard ratio of 1.49 (95% CI 1.06‐2.09) per 0.1 increase in model output. Conclusions: Our findings elucidate the feasibility of deep learning–based AF risk prediction using single-NSR recordings from mobile devices, highlighting the potential for remote AF management in real-world populations. The model output may serve as a risk indicator to support opportunistic AF screening, prompting further clinical evaluation and informing decisions about more intensive monitoring.
- Open Access
- 8 January 2026
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 13 (1)
Residual congestion at discharge assessed by bioelectrical impedance and its prognostic value in acute heart failure: a multi-centre, prospective registry study
Introduction: Residual congestion at discharge is an important risk factor for early readmission and mortality in acute heart failure (AHF); however, it is often underestimated. This study aimed to evaluate the clinical value of oedema index (EI) and phase angle (PA) from bioelectrical impedance analysis (BIA) in assessing residual congestion and predicting short-term outcomes in patients with AHF. Methods: A multi-centre registry database from the steady movement with innovating leadership for heart failure (HF) between 2019 and 2023 was analysed. EI and PA were measured using direct segmental multi-frequency BIA device. The worsening heart failure events (WHF) were defined as a composite of HF readmission and all-cause mortality at 90- and 180-days. Receiver operating characteristic analysis determined the EI and PA cut-off values. Logistic regression and Cox proportional hazard analyses were used to assess the associations between BIA parameters and clinical outcomes. Results: A total of 600 patients were included, of whom 360 (60%) were male, with a median age of 72.1 years. Within 180 days, 63 patients (11%) experienced WHFs. EI (odds ratio [OR] 1.83; 95% confidence interval [CI] 1.43–2.35 at 90 days, OR 1.76; CI 1.44–2.14 at 180 days, all P < .01) and PA (OR 0.93; CI 0.90–0.96 at 90 days, OR 0.94; CI 0.91–0.96 at 180 days, all P < .01) showed correlation in univariate analysis. EI ≥ 0.4 and PA < 4.5° were identified as prognostic thresholds for unfavourable outcomes, with predictive values of 75% (P < .01, sensitivity 83%, and specificity 56%), and 71% (P < .01, sensitivity 81%, and specificity 54%), respectively. Increased EI (adjusted hazard ratio [aHR] 1.71; CI 1.26–2.31 at 90 days, aHR 1.64; CI 1.30–2.07 at 180 days, all P < .01) and decreased PA (aHR 0.91; CI 0.86–0.96 at 90 days, aHR 0.92; CI 0.89–0.97 at 180 days, all P < .01) were independently associated with WHFs. Based on the estimated cut-offs, when EI and PA were considered together to classify the high-risk BIA group (EI ≥ 0.4 and PA < 4.5°), the risk was apparently increased (aHR 6.79; CI 1.71–26.93 at 90 days, aHR 3.43; CI 1.41–8.32 at 180 days, all P < .05) compared with normal BIA (EI < 0.4 and PA ≥ 4.5°) group. Conclusion: The EI and PA measured at discharge independently predicted short-term WHFs in patients with AHF. The suggested thresholds for identifying patients at high-risk of residual congestion were EI ≥ 0.4 and PA < 4.5°. As a non-invasive and accessible modality, BIA holds promise as a complementary tool to established biomarkers for evaluating congestion at discharge.
- 8 January 2026
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 13 (1)
Open AccessResidual congestion at discharge assessed by bioelectrical impedance and its prognostic value in acute heart failure: a multi-centre, prospective registry study
Introduction: Residual congestion at discharge is an important risk factor for early readmission and mortality in acute heart failure (AHF); however, it is often underestimated. This study aimed to evaluate the clinical value of oedema index (EI) and phase angle (PA) from bioelectrical impedance analysis (BIA) in assessing residual congestion and predicting short-term outcomes in patients with AHF. Methods: A multi-centre registry database from the steady movement with innovating leadership for heart failure (HF) between 2019 and 2023 was analysed. EI and PA were measured using direct segmental multi-frequency BIA device. The worsening heart failure events (WHF) were defined as a composite of HF readmission and all-cause mortality at 90- and 180-days. Receiver operating characteristic analysis determined the EI and PA cut-off values. Logistic regression and Cox proportional hazard analyses were used to assess the associations between BIA parameters and clinical outcomes. Results: A total of 600 patients were included, of whom 360 (60%) were male, with a median age of 72.1 years. Within 180 days, 63 patients (11%) experienced WHFs. EI (odds ratio [OR] 1.83; 95% confidence interval [CI] 1.43–2.35 at 90 days, OR 1.76; CI 1.44–2.14 at 180 days, all P < .01) and PA (OR 0.93; CI 0.90–0.96 at 90 days, OR 0.94; CI 0.91–0.96 at 180 days, all P < .01) showed correlation in univariate analysis. EI ≥ 0.4 and PA < 4.5° were identified as prognostic thresholds for unfavourable outcomes, with predictive values of 75% (P < .01, sensitivity 83%, and specificity 56%), and 71% (P < .01, sensitivity 81%, and specificity 54%), respectively. Increased EI (adjusted hazard ratio [aHR] 1.71; CI 1.26–2.31 at 90 days, aHR 1.64; CI 1.30–2.07 at 180 days, all P < .01) and decreased PA (aHR 0.91; CI 0.86–0.96 at 90 days, aHR 0.92; CI 0.89–0.97 at 180 days, all P < .01) were independently associated with WHFs. Based on the estimated cut-offs, when EI and PA were considered together to classify the high-risk BIA group (EI ≥ 0.4 and PA < 4.5°), the risk was apparently increased (aHR 6.79; CI 1.71–26.93 at 90 days, aHR 3.43; CI 1.41–8.32 at 180 days, all P < .05) compared with normal BIA (EI < 0.4 and PA ≥ 4.5°) group. Conclusion: The EI and PA measured at discharge independently predicted short-term WHFs in patients with AHF. The suggested thresholds for identifying patients at high-risk of residual congestion were EI ≥ 0.4 and PA < 4.5°. As a non-invasive and accessible modality, BIA holds promise as a complementary tool to established biomarkers for evaluating congestion at discharge.
- Open Access
- 1 January 2026
- Published by XMLink in Journal of Lipid and Atherosclerosis
- Vol. 15 (3) , 544-554
Cardiovascular Risk Associated With General and Abdominal Obesity in Young Adults Without Traditional Risk Factors: A Korean Nationwide Cohort Study
Lee JH, et al. J Lipid Atheroscler. 2026 Sep;15(3):544-554. https://doi.org/10.12997/jla.2026.15.3.544
- 1 January 2026
- Published by XMLink in Journal of Lipid and Atherosclerosis
- Vol. 15 (3) , 544-554
Open AccessCardiovascular Risk Associated With General and Abdominal Obesity in Young Adults Without Traditional Risk Factors: A Korean Nationwide Cohort Study
Lee JH, et al. J Lipid Atheroscler. 2026 Sep;15(3):544-554. https://doi.org/10.12997/jla.2026.15.3.544
- Open Access
- 1 January 2026
- Published by XMLink in Korean Circulation Journal
- Vol. 56 (11) , 1008
Association Between Serum Cortisol Levels and Variant Angina
Lee JH, et al. Korean Circ J. 2026 ;56:e80. https://doi.org/10.4070/kcj.2025.0375
- 1 January 2026
- Published by XMLink in Korean Circulation Journal
- Vol. 56 (11) , 1008
Open AccessAssociation Between Serum Cortisol Levels and Variant Angina
Lee JH, et al. Korean Circ J. 2026 ;56:e80. https://doi.org/10.4070/kcj.2025.0375
- Open Access
- 1 January 2024
- Published by XMLink in International Journal of Heart Failure
- Vol. 6 (3) , 129-136
Rationale, Design, and Interim Observations of the Steady Movement With Innovating Leadership for Heart Failure (SMILE HF) Registry: A Multicenter Prospective Cohort Registry for Patients With Acute Heart Failure
Choi JY, et al. Int J Heart Fail. 2024 Jul;6(3):129-136. https://doi.org/10.36628/ijhf.2024.0014
- 1 January 2024
- Published by XMLink in International Journal of Heart Failure
- Vol. 6 (3) , 129-136
Open AccessRationale, Design, and Interim Observations of the Steady Movement With Innovating Leadership for Heart Failure (SMILE HF) Registry: A Multicenter Prospective Cohort Registry for Patients With Acute Heart Failure
Choi JY, et al. Int J Heart Fail. 2024 Jul;6(3):129-136. https://doi.org/10.36628/ijhf.2024.0014
- Open Access
- 1 January 2023
- Published by XMLink in Journal of Korean Medical Science
- Vol. 38 (39) , e334
A Correlative Relationship Between Heart Failure and Cognitive Impairment: A Narrative Review
Park MS, et al. J Korean Med Sci. 2023 Sep;38(39):e334. https://doi.org/10.3346/jkms.2023.38.e334
- 1 January 2023
- Published by XMLink in Journal of Korean Medical Science
- Vol. 38 (39) , e334
Open AccessA Correlative Relationship Between Heart Failure and Cognitive Impairment: A Narrative Review
Park MS, et al. J Korean Med Sci. 2023 Sep;38(39):e334. https://doi.org/10.3346/jkms.2023.38.e334
- Open Access
- 14 October 2022
- Published by Korean Society of Heart Failure in International Journal of Heart Failure
- Vol. 4 (4) , 205-208
Acute Myocarditis After COVID-19 Vaccination
Cheon DY, et al. Int J Heart Fail. 2022 Oct;4:e19. https://doi.org/10.36628/ijhf.2022.0019
- 14 October 2022
- Published by Korean Society of Heart Failure in International Journal of Heart Failure
- Vol. 4 (4) , 205-208
Open AccessAcute Myocarditis After COVID-19 Vaccination
Cheon DY, et al. Int J Heart Fail. 2022 Oct;4:e19. https://doi.org/10.36628/ijhf.2022.0019
- Open Access
- 8 December 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (12) , e0261072
Current status of cardiac rehabilitation among representative hospitals treating acute myocardial infarction in South Korea
Cardiac rehabilitation services are mostly underutilized despite the documentation of substantial morbidity and mortality benefits of cardiac rehabilitation post-acute myocardial infarction. To assess the implementation rate and barriers to cardiac rehabilitation in hospitals dealing with acute myocardial infarction in South Korea, between May and July 2016, questionnaires were emailed to cardiology directors of 93 hospitals in South Korea; all hospitals were certified institutes for coronary interventions. The questionnaires included 16 questions on the hospital type, cardiology practice, and implementation of cardiac rehabilitation. The obtained data were categorized into two groups based on the type of the hospital (secondary or tertiary) and statistically analysed. Of the 72 hospitals that responded (response rate of 77%), 39 (54%) were tertiary medical centers and 33 (46%) were secondary medical centers. All hospitals treated acute myocardial infarction patients and performed emergency percutaneous coronary intervention; 79% (57/72) of the hospitals performed coronary artery bypass grafting. However, the rate of implementation of cardiac rehabilitation was low overall (28%, 20/72 hospitals) and even lower in secondary medical centers (12%, 4/33 hospitals) than in tertiary centers (41%, 16/39 hospitals, p = 0.002). The major barriers to cardiac rehabilitation included the lack of staff (59%) and lack of space (33%). In contrast to the wide availability of acute-phase invasive treatment for AMI, the overall implementation of cardiac rehabilitation is extremely poor in South Korea. Considering the established benefits of cardiac rehabilitation in patients with acute myocardial infarction, more administrative support, such as increasing the fee for cardiac rehabilitation services by an appropriate level of health insurance coverage should be warranted.
- 8 December 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (12) , e0261072
Open AccessCurrent status of cardiac rehabilitation among representative hospitals treating acute myocardial infarction in South Korea
Cardiac rehabilitation services are mostly underutilized despite the documentation of substantial morbidity and mortality benefits of cardiac rehabilitation post-acute myocardial infarction. To assess the implementation rate and barriers to cardiac rehabilitation in hospitals dealing with acute myocardial infarction in South Korea, between May and July 2016, questionnaires were emailed to cardiology directors of 93 hospitals in South Korea; all hospitals were certified institutes for coronary interventions. The questionnaires included 16 questions on the hospital type, cardiology practice, and implementation of cardiac rehabilitation. The obtained data were categorized into two groups based on the type of the hospital (secondary or tertiary) and statistically analysed. Of the 72 hospitals that responded (response rate of 77%), 39 (54%) were tertiary medical centers and 33 (46%) were secondary medical centers. All hospitals treated acute myocardial infarction patients and performed emergency percutaneous coronary intervention; 79% (57/72) of the hospitals performed coronary artery bypass grafting. However, the rate of implementation of cardiac rehabilitation was low overall (28%, 20/72 hospitals) and even lower in secondary medical centers (12%, 4/33 hospitals) than in tertiary centers (41%, 16/39 hospitals, p = 0.002). The major barriers to cardiac rehabilitation included the lack of staff (59%) and lack of space (33%). In contrast to the wide availability of acute-phase invasive treatment for AMI, the overall implementation of cardiac rehabilitation is extremely poor in South Korea. Considering the established benefits of cardiac rehabilitation in patients with acute myocardial infarction, more administrative support, such as increasing the fee for cardiac rehabilitation services by an appropriate level of health insurance coverage should be warranted.
- Open Access
- 1 October 2021
- Published by Elsevier in Clinical Therapeutics
- Vol. 43 (10) , 1735-1747
Efficacy and Safety of Fenofibrate-Statin Combination Therapy in Patients With Inadequately Controlled Triglyceride Levels Despite Previous Statin Monotherapy: A Multicenter, Randomized, Double-blind, Phase IV Study
- 1 October 2021
- Published by Elsevier in Clinical Therapeutics
- Vol. 43 (10) , 1735-1747
Open AccessEfficacy and Safety of Fenofibrate-Statin Combination Therapy in Patients With Inadequately Controlled Triglyceride Levels Despite Previous Statin Monotherapy: A Multicenter, Randomized, Double-blind, Phase IV Study